Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04291300
Other study ID # MOHN18
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date May 26, 2020
Est. completion date February 13, 2023

Study information

Verified date May 2023
Source Radboud University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Phase 2 pilot study, which evaluates the safety and efficacy of Lutetium-177-PSMA radioligand therapy in advanced salivary gland cancer patients.


Description:

Rationale: Prostate specific membrane antigen (PSMA) is a transmembrane protein, which is expressed on prostate cancers cells and other malignancies. Recently, several ligands have been developed that target PSMA. Linked to Gallium-68, this enables diagnostic 68Ga-PSMA-PET/CT scans. Linked to Lutetium-177 enables therapeutic 177Lu-PSMA Radioligand therapy. Most research on the diagnostic and therapeutic possibilities of PSMA has been conducted in patients with advanced prostate cancer. This research group investigates whether these findings also apply to salivary gland cancer (SGC), a rare cancer. Previously the investigators conducted a phase II 68Ga-PSMA imaging study (NCT03319641), to evaluate PSMA ligand uptake in locally advanced, recurrent and metastatic (R/M) ACC and SDC (two subtypes of SGC). A relevant PSMA-ligand uptake was observed in 93% of ACC patients and 40% of SDC patients. Therefore we consider 177Lu-PSMA radioligand therapy a potential new treatment option for these subtypes of SGC. Objective: To evaluate the safety and efficacy of 177Lu-PSMA RLT in patients with R/M ACC and SDC with PSMA ligand uptake. Study design: Phase II pilot study, single centre, two cohorts.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date February 13, 2023
Est. primary completion date February 13, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients must have the ability to provide written informed consent. - Patients must be = 18 years of age. - Patients must have an ECOG performance status of 0 to 2. - Patients must have histological, pathological, and/or cytological confirmation of either adenoid cystic carcinoma or salivary duct carcinoma. - Patients must have incurable, local or regional recurrent or metastatic ACC or SDC. - Patients with ACC can only participate in case of objective growth in the last three months or complaints due to the disease. - Patients must have adequate organ function: - Sufficient bone marrow capacity as defined by: WBC count (white blood cell) =2.5x10^9/L, PLT (platelet) count =100x10^9/L, Hb =6 mmol/L, absolute neutrophil count (ANC) =1.5x10^9/L - Adequate liver function as defined by:Total bilirubin =1.5 x ULN. For patients known with Gilbert's Syndrome = 3 x ULN is permitted. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =3.0 × ULN OR =5.0 × ULN for patients with liver metastases. - Adequate kidney function as defined by:serum creatinine =1.5 x ULN or creatinine clearance = 50 mL/min - Patients must have measurable disease at baseline. Defined as = 1 lesion = 2 cm (long axis) that is present on baseline CT. - Patients must have a positive 68Ga-PSMA PET/CT scan, defined by at least one lesion = 1.5 cm (long axis) with a ligand uptake above liver level. Exclusion Criteria: - Patients whom are pregnant or breast feeding. - Patients with reproductive potential not implementing adequate contraceptives measures. - Patients with known brain metastases or cranial epidural disease or intracardial metastases. - Patients with concurrent serious (as determined by the Principal Investigator) medical conditions, including, but not limited to, New York Heart Association class III or IV congestive heart failure, history of congenital prolonged QT syndrome, uncontrolled infection, active hepatitis B or C, or other significant co-morbid conditions that in the opinion of the investigator would impair study participation or cooperation. - Patients with urinary tract obstruction or marked hydronephrosis - Less than 4 weeks since last myelosuppressive therapy or other radionuclide therapy. - Concomitant cancer treatments

Study Design


Intervention

Drug:
Lutetium-177-PSMA-I&T
4 cycles of 7.4 GBq 177Lu-PSMA every 6 weeks.

Locations

Country Name City State
Netherlands Radboudumc Nijmegen Gelderland

Sponsors (2)

Lead Sponsor Collaborator
Radboud University Medical Center Dutch Cancer Society

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse events measured using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Safety Through study completion, up until 3 years after last patient commences treatment
Secondary Objective response rate (ORR) Response will be measured according to RECIST version 1.1 Through study completion, up until 3 years after last patient commences treatment
Secondary Progression free survival (PFS) PFS will be defined as time from study enrollment until disease progression or death. Through study completion, up until 3 years after last patient commences treatment
Secondary Overall survival (OS) OS will be defined as time from study enrollment until date of death of any cause. Through study completion, up until 3 years after last patient commences treatment
Secondary Duration of response (DoR) Only patients with complete remission or partial response will be included in the assessment of DoR. DoR is defined as time from study enrollment until disease progression or death Through study completion, up until 3 years after last patient commences treatment
Secondary Quality of life (QoL) QoL will be assessed using EORTC QLQ-C30 questionnaire. This is the core questionnaire for assessing health related quality of life of cancer patients participating in clinical trials. It contains 30 items and incorporates a global health status scale, five functional scales, three symptom scales, and several single items assessing additional symptoms. All of the scales and single-item measures range from 0-100. A high score for global health status represents a high QoL, a high score in functional scale represents a high/healthy level of functioning, a high score for a symptom scale/item represents a high level of symptomatology/problems. Trough study completion, up until 3 years after last patient commences treatment
Secondary Quality of life (QoL) QoL will be assessed using EORTC QLQ-H&N43 questionnaire. This is an additional questionnaire to assess health related topics relevant for head and neck cancer patients. The module contains 43 questions, all symtom scales or symptom items.All of the scale/item measures range from 0-100. For all scales/items higher scores indicate more problems. Trough study completion, up until 3 years after last patient commences treatment
Secondary Quality of life (QoL) QoL will be assessed using performance status scale for head&neck cancer patients (PSS-HN). It contains 3 items, each randing from 0-100. These items are rated by the health professional. A high score indicates a high performance status. Trough study completion, up until 3 years after last patient commences treatment
Secondary Quality of life (QoL) QoL will be assessed using pain visual analogue scale (VAS) questionnaire. This include two questions: the average pain during the past week and the worst pain during the past week. Both questions range from 0-100, a higher score indicates more pain. Trough study completion, up until 3 years after last patient commences treatment
Secondary Dosimetry Delivered doses will be calculated based on pharmacokinetics in the blood and dosimetry on SPECT/CT imaging. From start of study till last patient commences last SPECT/CT (7 days after first treatment cycle)
See also
  Status Clinical Trial Phase
Recruiting NCT04973683 - AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer Phase 1
Completed NCT01417143 - Dovitinib in Adenoid Cystic Carcinoma Phase 2
Recruiting NCT04140526 - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Phase 1/Phase 2
Active, not recruiting NCT05010629 - 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma Phase 2
Recruiting NCT04801264 - Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617 Early Phase 1
Completed NCT03319641 - PSMA-PET Imaging for Advanced ACC/SDC N/A
Recruiting NCT02942693 - Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma Phase 2
Completed NCT00581360 - Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck Phase 2
Not yet recruiting NCT05553782 - Drug Screening Using Novel IMD in ACC and Salivary Cancers Early Phase 1
Active, not recruiting NCT02775370 - A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck Phase 2
Active, not recruiting NCT02780310 - Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma Phase 2
Completed NCT04119453 - A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC) Phase 2
Active, not recruiting NCT02098538 - Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Phase 2
Completed NCT01558661 - Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Phase 2
Completed NCT01524692 - Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma Phase 2
Recruiting NCT03556228 - Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma Phase 1
Not yet recruiting NCT06462183 - Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC) Phase 1
Recruiting NCT01192087 - Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy Phase 1/Phase 2
Recruiting NCT04209660 - Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers Phase 2
Recruiting NCT05774899 - CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC Phase 1/Phase 2